قالب وردپرس درنا توس
Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Business https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Johnson & Johnson has a strong profit and 4Q revenue

Johnson & Johnson has a strong profit and 4Q revenue



A major leap in sales of prescription drugs, especially abroad, helped Johnson & Johnson to fluctuate to a large fourth-quarter surplus after spending a major loss a year ago when it charged 13.6% billions of dollars at the end of 201

7 US taxes overhaul.

The world's largest producer of healthcare products has also benefited from an effective tax rate of 2.6 percent for the last quarter, which amounted to only $ 80 million. That was the main reason why the J&J peaked Wall Street profit expectations, writes Investor Credit Suisse Vamil Divan analyst.

The company also reported lower research and development costs, restructuring and interest charges.

In premarket trading, J & J shares fell $ 1.99 or 1.5 percent to $ 128.70.

The manufacturer of baby shampoos and biotechnology on Tuesday reported a net income of $ 3.04 billion. Or $ 1.12 per. Share for 2018 fourth quarter. A year earlier, J & J reported a rare net loss – $ 10.71bn. Or $ 3.00 pr. Share. This was due to the $ 13.6 billion tax for a year's tax payment of accumulated foreign earnings of over $ 66 billion returned to the United States with low tax rates.

Last quarter earnings adjusted for gains and expenses came to $ 1.97 per share. share or 2 cents better than industry analysts expected, according to a study by Zacks Investment Research.

New Brunswick, New Jersey-based company said revenue amounted to $ 20.39 billion. expectations, although only 1 percent higher than the fourth quarter of 2017.

J & J & # 39; s prescription pharmaceutical company, as usual, ran the strong performance with revenue of 5.3 percent to $ 10.19 billion. USD. The sale of cancer drugs, including Darzalex, Imbruviga and Zytiga, jumped 22 percent to a total of 2.49 billion. Dollars and sales of Remicade, Simponi and Stelara for rheumatoid arthritis and other immune disorders rose 8.3 percent to a total of $ 3.34 billion. $.

Johnson & Johnson's consumer health business accounted for a flat sale of $ 3.54 billion. Dollars, while medical equipment and the diagnostics company has been around for some years, so sales fell 4.4 percent to 6.67 billion. USD.

For the whole of 2018, Johnson & Johnson reported revenue of DKK 81.58 billion. DKK, An increase of 6.7 percent and a net income of DKK 15.3 billion. USD or $ 5.61 per Share.

Johnson & Johnson expects full-year earnings between $ 8.50 and $ 8.65 per year. Share with a turnover of DKK 80.4 billion USD and USD 81.2 billion . Industrial analysts have expected earnings of $ 8.60 and revenue of approx. $ 82.6 billion.

____

Follow Linda A. Johnson at https://twitter.com/LindaJ_onPharma

_____[19659015] Portions of this story were generated by automated insights (http://automatedinsights.com/ap) by using data from Zacks Investment Research.


Source link